Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.
How Hims & Hers Health Is Quietly Changing Healthcare
Hims surpassed 2.4 million subscribers with 95% recurring revenue and over 85% retention, driving 111% YoY revenue growth. Average monthly revenue per subscriber rose 50% YoY, showing strong monetization through personalization, bundling, and chronic care expansion. Despite Novo deal fallout, Hims continues scaling GLP-1 offerings and accelerating proprietary semaglutide development amid regulatory scrutiny.
All You Need to Know About Hims & Hers Health (HIMS) Rating Upgrade to Strong Buy
Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Stock Surges 90.4% in 3 Months: What's Fueling the Rally?
HIMS benefits from strong online revenue, subscriber growth, and global expansion moves to fuel its health platform momentum. However, challenges may hurt performance.
Why Hims & Hers Management Might Be Its Most Valuable Asset
Hims & Hers Health is a telehealth leader with strong revenue growth, innovative personalized solutions, and ambitious global expansion plans. Despite traditional valuation metrics suggesting overvaluation, I see long-term growth potential driven by top management strategic decisions, AI, new products, and international markets. Key risks include high stock-based compensation, regulatory scrutiny around compounded drugs, and intensifying competition from major healthcare players.
Hims & Hers to offer generic semaglutide in Canada starting in 2026
Hims & Hers (NYSE:HIMS) announced plans to expand its digital health and weight loss services to Canada in 2026, coinciding with the first global availability of generic semaglutide. Beginning in January 2026, Canada will become the first country to offer generic versions of semaglutide, a GLP-1 receptor agonist widely used for weight management under brand names such as Wegovy and Ozempic.
Hims & Hers to offer generic semaglutide in Canada as Novo Nordisk patent lapses
Hims & Hers Health announced plans to expand to Canada in 2026. Hims will offer generic copies of semaglutide drugs in Canada as Novo Nordisk loses patent protection.
Hims & Hers Health: Unlocking A $6 Billion Future
Hims & Hers grew Q1 2025 revenue by 111% to $586 million, with adjusted EBITDA nearly tripling to $91 million. Nearly 60% of the 2.4 million subscribers now use personalized treatments, boosting retention and average revenue per user to $84. Despite the Novo Nordisk split, the diversified GLP-1 and weight loss portfolio targets $725 million in 2025 specialty revenue.
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.
